Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

During the COVID-19 pandemic, research on "cytokine storms" has been reinvigorated in the field of infectious disease, but it also has particular relevance to cancer research. Interleukin-6 (IL-6) has emerged as a key component of the immune response to SARS-CoV-2, such that the repurposing of anti-IL-6 therapeutics for COVID-19 is now a major line of investigation, with several ongoing clinical trials. We lay a framework for understanding the role of IL-6 in the context of cancer research and COVID-19 and suggest how lessons learned from cancer research may impact SARS-CoV-2 research and vice versa.

More information Original publication

DOI

10.1016/j.ccell.2020.09.019

Type

Journal article

Publication Date

2020-11-09T00:00:00+00:00

Volume

38

Pages

598 - 601

Total pages

3

Keywords

Betacoronavirus, COVID-19, Coronavirus Infections, Cytokines, Humans, Inflammation, Neoplasms, Pandemics, Pneumonia, Viral, SARS-CoV-2, Severity of Illness Index